|Slideshows|July 9, 2021

COVID-19 Blues

Research confirms COVID-19’s negative impact on Americans’ mental health.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated

ByLeah Kuntz

May 20th 2026

Antidepressant Use in Pregnancy & Autism/ADHD in Children: Most Comprehensive Study to Date Finds No Clear Link

ByLeah Kuntz

May 14th 2026

Treatment of Inflammation to Relieve Depression and Anhedonia

ByKenneth J. Bender, PharmD, MA

May 12th 2026

Podcast: Psychedelics for Depression and Other Mental Health Conditions. The Way Forward With Guy Goodwin, MD

ByJoseph F. Goldberg, MD,Guy Goodwin, MD

May 8th 2026

The SAINT Trial: Expanding rTMS for Postpartum Depression

ByThalia Robakis, MD, PhD

April 30th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

COVID-19 Blues

Related Content

SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated

Antidepressant Use in Pregnancy & Autism/ADHD in Children: Most Comprehensive Study to Date Finds No Clear Link

Treatment of Inflammation to Relieve Depression and Anhedonia

Podcast: Psychedelics for Depression and Other Mental Health Conditions. The Way Forward With Guy Goodwin, MD

The SAINT Trial: Expanding rTMS for Postpartum Depression

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

New Name, New Path for Psychiatry: The Future of the DSM

Endangered Education: Psychiatric Professional Degrees Under Attack

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy